Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis

By Cheer S.M.   Waugh J.   Noble S.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2501-2520

Adis International

Access to resources Recommend Favorite

Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies

By Hassett Daniel J   Korfhagen Thomas R   Irvin Randall T   Schurr Michael J   Sauer Karin   Lau Gee W   Sutton Mark D   Yu Hongwei   Hoiby Niels  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 2, 2010-02 ,pp. : 117-130

Informa Healthcare

Access to resources Recommend Favorite

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials

By Máiz Luis   Girón Rosa M   Olveira Casilda   Quintana Esther   Lamas Adelaida   Pastor Dolores   Cantón Rafael   Mensa Josep  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1135-1149

Informa Healthcare

Access to resources Recommend Favorite

Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

By Ehsan Zarmina   Wetzel Jacqueline Denise   Clancy John P  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 743-749

Informa Healthcare

Access to resources Recommend Favorite

Bayesian Optimisation of Tobramycin Dosing in Paediatric Patients with Cystic Fibrosis

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 3, 2011-09 ,pp. : 183-187

John Wiley & Sons Inc

Access to resources Recommend Favorite